


## Eleclazine hydrochloride

### Chemical Properties

CAS No. : 1448754-43-5  
 Formula: C<sub>21</sub>H<sub>17</sub>ClF<sub>3</sub>N<sub>3</sub>O<sub>3</sub>  
 Molecular Weight: 451.83  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
*Actual storage temperature shall be subject to the COA.*



### Biological Description

Description	Eleclazine hydrochloride (GS 6615 hydrochloride) is a novel inhibitor of late Na <sup>+</sup> current (IC <sub>50</sub> : 0.7 μM).
Targets(IC <sub>50</sub> )	Potassium Channel,Sodium Channel
In vitro	Inhibition by GS-6615 of ATX-II enhanced late I <sub>Na</sub> is potently correlated with shortening of myocyte APD and isolated heart MAPD[1]. Eleclazine hydrochloride inhibits ATX-II enhanced late I <sub>Na</sub> in ventricular myocytes, shorten the ATX-II induced prolongation of APD, MAPD, QT interval. It also decreased spatiotemporal dispersion of repolarization and ventricular arrhythmias. Selective inhibition of cardiac late I <sub>Na</sub> with eleclazine hydrochloride confers dual protection against vulnerability to ischemia-induced AF. That decreases atrial and ventricular repolarization abnormalities before and during adrenergic stimulation without negative inotropic effects. [2]

### Solubility Information

Solubility	DMSO: 100 mg/mL (221.32 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.85 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	2.2132 mL	11.0661 mL	22.1322 mL
5 mM	0.4426 mL	2.2132 mL	4.4264 mL
10 mM	0.2213 mL	1.1066 mL	2.2132 mL
50 mM	0.0443 mL	0.2213 mL	0.4426 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Rajamani S et al. The novel late Na<sup>+</sup> current inhibitor, GS-6615 (eleclazine) and its anti-arrhythmic effects in rabbit isolated heart preparations. *Br J Pharmacol.* 2016 Jul 23.

Justo F et al. Inhibition of the cardiac late sodium current with eleclazine protects against ischemia-induced vulnerability to atrial fibrillation and reduces atrial and ventricular repolarization abnormalities in the absence and presence of concurrent adrenergic stimulation. *Heart Rhythm.* 2016 Sep;13(9):1860-7.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481